Motif Neurotech develops wireless, implantable neural interfaces for the peripheral nervous system. Their devices support high-channel-count recording and stimulation, enabling precise mapping and modulation of neural activity outside the brain. The technology targets applications in neuromodulation therapies for chronic pain, prosthetics control, and sensory restoration. Customers include academic researchers, clinical investigators, and medical device developers. The company operates in the neurotechnology and medtech markets, focusing on bioelectronic medicine. Motif Neurotech raised $12 million in seed funding in 2023, led by Khosla Ventures with participation from other investors. Jacob Robinson, the CEO and co-founder, previously worked at Neuralink on neural interface hardware. The company is based in the San Francisco Bay Area.